Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of BBT-401-1S in Patients With Active Ulcerative Colitis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2022
Price :
$35
*
At a glance
- Drugs BBT-401 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Bridge Biotherapeutics
- 01 Jun 2021 According to a Bridge Biotherapeutics media release, interim data of the medium to high dose study is expected to be disclosed in the first half of 2022.
- 15 Oct 2020 Status changed from active, no longer recruiting to discontinued.
- 22 Sep 2020 According to a Bridge Biotherapeutics media release,the company confirmed the safety and efficacy profile of BBT-401 in the first cohort study and plans to initiate the mid to high dose cohort trials by early 2021. Additionally, the company will expand the number of trial sites to approximately 40 sites.